Acumen Pharmaceuticals (ABOS) Q4 2025 earnings summary

Executive summary

• Achieved significant clinical progress in 2025 with the phase II ALTITUDE-AD trial for sabirnetug, targeting Aβ oligomers in Alzheimer's disease, and expanded the pipeline with the EBD program in partnership with JCR Pharmaceuticals.

• Completed enrollment for ALTITUDE-AD, with high participant rollover into the 12-month open label extension (OLE) starting November 2025.

• Preclinical EBD data exceeded target profiles, supporting multiple viable candidates and catalyzing a $35.75M private placement in March 2026.

• ALTITUDE-AD phase II topline results expected late 2026, with IND filing for EBD clinical candidate targeted for mid-2027.

• Cash position of $116.9M at year-end 2025 expected to fund operations into early 2027.

Financial highlights

• Ended 2025 with $116.9M in cash and marketable securities, down from $136.1M at September 30, 2025.

• R&D expenses rose to $104.9M in 2025, driven by ALTITUDE-AD trial costs, personnel, and EBD research.

• G&A expenses decreased to $18.9M in 2025, mainly due to lower recruiting, insurance, and consulting costs.

• Net loss for 2025 was $121.3M, up from $102.3M in 2024.

• Closed a $35.75M private placement in March 2026 to support EBD program and general corporate purposes.

Outlook and guidance

• ALTITUDE-AD phase II efficacy and safety data expected late 2026.

• IND filing for EBD clinical candidate targeted for mid-2027.

• Cash reserves projected to support operations into early 2027.

• Anticipates one additional phase III study, similar to ALTITUDE-AD, may be sufficient for BLA filing if phase II is positive.

• Ongoing preclinical work and further data presentations planned for EBD program.